Abstract
SummaryA study of the structural analogs of diethylcarbamazine reveals the requirement for a carboxamide grouping and a saturated or unsaturated ring containing nitrogen for optimal inhibition of SRS-Arat release. Diethylcarbamazine and its analogs do not act by interfering with PMN leukocyte viability and they do not inhibit the homocytotropic antibody-mediated release of histamme and serotonin. Conversely, disodium cromoglycate suppresses the latter pathway without inhibiting the antigen-induced release of SRS-Arat. Neither diethylcarbamazine nor disodium cromoglycate antagonizes the pharmacologic activity of histamine or SRS-Arat. The use of these agents permits further dissociation of the pathways leading to the immunologic release of SRS-Arat and histamine in the rat by selective pharmacologic inhibition.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
